Page last updated: 2024-08-24

simendan and Cardiovascular Stroke

simendan has been researched along with Cardiovascular Stroke in 69 studies

Research

Studies (69)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.45)	18.2507
2000's	37 (53.62)	29.6817
2010's	23 (33.33)	24.3611
2020's	8 (11.59)	2.80

Authors

Authors	Studies
Chen, Y; Geng, Y; Jia, Z; Sun, X; Wei, J; Xie, Y; Xing, Z; Zhao, B; Zou, H	1
Yu, S; Zhang, J	1
Chen, ZJ; Cheng, YQ; Li, ZS; Liu, C; Pan, T; Sun, YH; Wang, DJ; Wang, K; Zhang, H; Zhang, HT	1
Bruno, RR; Jung, C; Kelm, M	1
Afzal, O; Akhtar, MS; Altamimi, A; Hassan, MZ; Hassan, Q; Mohammad, AAS; Sharma, AK; Tabassum, F	1
Belley-Côté, EP; Brodie, D; Combes, A; Di Santo, P; Fan, E; Fernando, SM; Hibbert, B; Lévy, B; Mathew, R; Rochwerg, B; Russo, JJ; Sadeghirad, B; Simard, T; Thiele, H; Tran, A; van Diepen, S	1
Bunte, S; Heinen, A; Hollmann, MW; Huhn, R; Mathes, A; Raupach, A; Sixt, SU; Stroethoff, M; Torregroza, C; van de Snepscheut, M	1
Efremov, L; Frantz, S; Mikolajczyk, R; Schumann, J; Sedding, D; Tongers, J; Uhlig, K	1
Feige, K; Heinen, A; Hollmann, MW; Huhn, R; Raupach, A; Ruske, R; Stroethoff, M; Torregroza, C; Yueksel, B	1
Alexander, JH; Anstrom, KJ; Argenziano, M; Bozinovski, J; Duncan, A; Fremes, S; Goodman, SG; Harrington, RA; Harrison, RW; Hay, D; Heringlake, M; Jankowich, R; Kalavrouziotis, D; Leimberger, JD; Levy, JH; Luber, J; Marcel, R; Mehta, RH; Meza, J; Murphy, E; Nagpal, D; Park, S; Soltesz, EG; Toller, W; van Diepen, S; Wang, A	1
Cao, H; Fang, M; Wang, Z	1
Frantz, S; Henrich, EC; Prondzinsky, R; Schumann, J; Strobl, H; Thiele, H; Unverzagt, S; Weiche, S; Werdan, K	1
El-Kherbetawy, MK; Makary, S; Tawfik, MK	1
Behmenburg, F; Bongartz, A; Bunte, S; Heinen, A; Hollmann, MW; Huhn, R; Minol, JP; Raupach, A; Sixt, SU; Stroethoff, M	1
Chen, L; He, Y; Qing, X; Zhang, Y; Zhu, J	1
Buerke, M; Haerting, J; Hirsch, K; Prondzinsky, R; Thiele, H; Unverzagt, S; Wachsmuth, L; Werdan, K	1
Lanzillo, C; Mustilli, M; Romagnoli, E; Sette, A; Summaria, F	1
Høydal, MA; Kolseth, SM; Nordhaug, DO; Rolim, NP; Salvesen, Ø; Wahba, A	1
Wu, J; Wu, X; Yan, X; Zhang, Y	1
Aliabadi, A; Buchberger, E; de Martin, R; Demyanets, S; Gröger, M; Hofer-Warbinek, R; Huber, K; Kastl, SP; Kaun, C; Krychtiuk, KA; Maurer, G; Pisoni, J; Rauscher, S; Speidl, WS; Watzke, L; Wojta, J; Zuckermann, A	1
Andersen, GØ; Arnesen, H; Bjørnerheim, R; Eritsland, J; Husebye, T; Mangschau, A; Seljeflot, I	1
Duvall, E; Haavisto, M; Kentala, R; Knuuti, J; Levijoki, J; Nyman, L; Pietilä, M; Roivainen, A; Saraste, A; Saukko, P; Saunavaara, V; Savunen, T; Stark, C; Strandberg, M; Tarkia, M; Teräs, M; Tolvanen, T; Vähäsilta, T	1
Chen, H; Li, L; Liu, T; Su, Q; Wang, J; Zhou, Y	1
Fuhrmann, JT; Rauwolf, T; Schmeisser, A; Schoen, SP; Schulze, MR; Strasser, RH; Weinbrenner, C; Wunderlich, C	1
Greif, M; Reithmann, C; Weis, M; Zwermann, L	1
Carrio, ML; Farrero, E; Miralles, A; Rodriguez-Castro, D; Ruiz-Majoral, A; Torrado, H; Ventura, JL	1
Anastasiou-Nana, MI; Drakos, SG; Kanakakis, J; Katsaros, F; Lazaris, N; Malliaras, K; Nanas, JN; Ntalianis, AS; Tsagalou, EP	1
Baumert, JH; Hein, M; Roehl, AB; Rossaint, R; Scherer, K; Steendijk, P	1
Landoni, G; Zambon, M; Zangrillo, A	1
Buerke, M; Carter, JM; Ebelt, H; Heinroth, K; Lemm, H; Prondzinsky, R; Russ, MA; Schlitt, A; Schmidt, H; Soeffker, G; Werdan, K; Winkler, M	1
Beute, J	1
Finckenberg, P; Forsten, H; Kaheinen, P; Kytö, V; Leskinen, H; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Tikkanen, I; Vahtola, E	1
Delle Karth, G; Heinz, G	1
Yalta, K; Yilmaz, MB; Yontar, OC	1
Baldassarri, R; Guarracino, F; Landoni, G; Nobile, L; Stefani, M	1
Albertsson, P; Boren, J; Grip, L; Hallgren, P; Holmberg, M; Matejka, G; Omerovic, E; Råmunddal, T	1
Beggino, C; Caimmi, PP; Crosio, E; Giustini, G; Grossini, E; Kapetanakis, EI; Micalizzi, E; Molinari, C; Reposo, G; Vacca, G	1
Kaheinen, P; Lakkisto, J; Lakkisto, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Storvik, M; Tikkanen, I; Vahtola, E	1
Cho, S; Hara, T; Higashijima, U; Maekawa, T; Matsumoto, S; Sumikawa, K; Tosaka, S	1
Andersen, GØ; Arnesen, H; Bjørnerheim, R; Eritsland, J; Husebye, T; Mangschau, A; Müller, C; Sandvik, L; Seljeflot, I	1
Coats, AJ	1
Andrejevs, N; Golikov, AP; Kobalava, ZD; Laine, T; Lazebnik, LB; Lehtonen, LA; Lie, KI; Moiseyev, VS; Nieminen, MS; Põder, P; Ruda, MY	1
Ambrosi, P; Andréjak, M; Gayet, JL	1
Blome, M; Boldt, J; Isgro, F; Lang, J; Lehmann, A	1
Ewert, P; Hetzer, R; Lange, PE; Luther, YC; Mühler, EG; Nasseri, B; Redlin, M; Schulze-Neick, I; Stiller, B	1
Giacomini, M; Iapichino, G; Noto, A; Palandi, A; Reali-Forster, C; Stabile, L	1
Reuter, H; Schwinger, RH; Zobel, C	1
Domínguez-Rodríguez, A; Ferrer-Hita, JJ; García-González, MJ	1
Andersen, GØ; Bjørnerheim, R; Eritsland, J; Jonassen, A; Kløw, NE; Mangschau, A	1
Alhashemi, JA	1
Benedetti, G; Bucciarelli-Ducci, C; Celotto, A; De Luca, L; Di Roma, A; Fedele, F; Genuini, I; Proietti, P; Sardella, G	1
Anis, L; Habib, H; Iheb, L; Moufida, H; Mustapha, F; Nedia, B	1
Battagliese, A; Benedetti, G; De Luca, L; Di Roma, A; Fedele, F; Proietti, P; Sardella, G	1
Abreu-González, P; Domínguez-Rodríguez, A; Ferrer-Hita, JJ; García-González, MJ; Muñoz, MB	1
Stranz, C; Toller, WG	1
Cammarata, GA; Fang, X; Huang, L; Sun, S; Tang, W; Weil, MH	1
Francis, D	1
Leprán, I; Papp, JG; Pollesello, P; Vajda, S; Varró, A	1
Berg, JS; Busk, M; Kristensen, J; Maeng, M; Mortensen, UM; Nielsen, TT; Nielsen-Kudsk, JE	1
Abreu-González, P; Domínguez-Rodríguez, A; García-González, MJ; Samimi-Fard, S	1
Das, B; Sarkar, C	1
Buerke, M; Christoph, A; Janusch, M; Lemm, H; Prondzinsky, R; Reith, S; Russ, M; Schlitt, A; Werdan, K	1
Buerke, M; Russ, M; Werdan, K	1
du Toit, EF; Genis, A; Lochner, A; Opie, LH; Pollesello, P	1
Auriti, A; Cianfrocca, C; Guido, V; Mercuro, G; Pasceri, V; Pelliccia, F; Santini, M	1
Kersten, JR; Montgomery, MW; Pagel, PS; Warltier, DC	1
Cleland, JG; Gomes, UC	1
Haikala, H; Kaheinen, P; Levijoki, J; Pollesello, P	1

Reviews

12 review(s) available for simendan and Cardiovascular Stroke

Article	Year
[Pharmaceutical therapy of infarct-related cardiogenic shock]. Deutsche medizinische Wochenschrift (1946), 2022, Volume: 147, Issue:18 Topics: Humans; Myocardial Infarction; Pharmaceutical Preparations; Shock, Cardiogenic; Shock, Septic; Simendan	2022
Inotropes, vasopressors, and mechanical circulatory support for treatment of cardiogenic shock complicating myocardial infarction: a systematic review and network meta-analysis. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2022, Volume: 69, Issue:12 Topics: Adult; Hemorrhage; Humans; Intra-Aortic Balloon Pumping; Myocardial Infarction; Network Meta-Analysis; Shock, Cardiogenic; Simendan; Treatment Outcome	2022
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. The Cochrane database of systematic reviews, 2020, 11-05, Volume: 11 Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Cause of Death; Dobutamine; Enoximone; Epinephrine; Humans; Hydrazones; Middle Aged; Myocardial Infarction; Nitric Oxide; Placebos; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan; Vasodilator Agents	2020
Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis. Medicina intensiva, 2018, Volume: 42, Issue:7 Topics: Cardiotonic Agents; Clinical Trials as Topic; Glomerular Filtration Rate; Hemodynamics; Humans; Length of Stay; Myocardial Infarction; Organ Dysfunction Scores; Oxygen; Risk; Shock, Cardiogenic; Simendan; Treatment Outcome	2018
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. The Cochrane database of systematic reviews, 2018, 01-29, Volume: 1 Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Cause of Death; Dobutamine; Enoximone; Humans; Hydrazones; Middle Aged; Myocardial Infarction; Nitric Oxide; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan; Vasodilator Agents	2018
Levosimendan in patients with low cardiac output syndrome undergoing cardiac surgery: A systematic review and meta-analysis. Anaesthesia, critical care & pain medicine, 2019, Volume: 38, Issue:3 Topics: Acute Kidney Injury; Cardiac Output; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Humans; Myocardial Infarction; Odds Ratio; Placebos; Postoperative Complications; Randomized Controlled Trials as Topic; Simendan; Time Factors	2019
BET 1: Levosimendan in cardiogenic shock secondary to acute myocardial infarction. Emergency medicine journal : EMJ, 2013, Volume: 30, Issue:12 Topics: Acute Disease; Cardiotonic Agents; Evidence-Based Emergency Medicine; Humans; Hydrazones; Male; Middle Aged; Myocardial Infarction; Pyridazines; Shock, Cardiogenic; Simendan; Treatment Outcome	2013
Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. The Cochrane database of systematic reviews, 2014, Jan-02, Issue:1 Topics: Cardiac Output, Low; Cardiotonic Agents; Dobutamine; Enoximone; Humans; Hydrazones; Myocardial Infarction; Nitric Oxide; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan; Vasodilator Agents	2014
Reducing perioperative myocardial infarction with anesthetic drugs and techniques. Current drug targets, 2009, Volume: 10, Issue:9 Topics: Anesthetics; Humans; Hydrazones; Myocardial Infarction; Perioperative Care; Pyridazines; Simendan; Vasodilator Agents	2009
[The best of clinical pharmacology in 2002]. Archives des maladies du coeur et des vaisseaux, 2003, Volume: 96 Spec No 1 Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Hormone Replacement Therapy; Humans; Hydrazones; Hypercholesterolemia; Losartan; Myocardial Infarction; Natriuretic Agents; Natriuretic Peptide, Brain; Neovascularization, Physiologic; Nicorandil; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Vasodilator Agents	2003
Levosimendan, a new inotropic and vasodilator agent. Anesthesiology, 2006, Volume: 104, Issue:3 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Calcium; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Heart Rate; Humans; Hydrazones; Myocardial Contraction; Myocardial Infarction; Phosphodiesterase Inhibitors; Potassium Channels; Pyridazines; Simendan; Vasodilator Agents	2006
[New pharmacological treatment approaches to cardiogenic shock]. Der Internist, 2007, Volume: 48, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiotonic Agents; Catecholamines; Complement C5; Complement Inactivating Agents; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Myocardial Infarction; Myocardial Revascularization; Nitric Oxide Synthase; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan; Survival Rate; Vasopressins	2007

Trials

13 trial(s) available for simendan and Cardiovascular Stroke

Article	Year
Effects of Levosimendan Preconditioning on Left Ventricular Remodeling after Myocardial Reperfusion in Acute Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention. The heart surgery forum, 2022, Jan-12, Volume: 25, Issue:1 Topics: Humans; Myocardial Infarction; Myocardial Reperfusion; Percutaneous Coronary Intervention; Simendan; Stroke Volume; Ventricular Function, Left; Ventricular Remodeling	2022
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. The New England journal of medicine, 2017, 05-25, Volume: 376, Issue:21 Topics: Aged; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Double-Blind Method; Female; Heart-Assist Devices; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Mortality; Myocardial Infarction; Perioperative Period; Postoperative Complications; Pyridazines; Renal Replacement Therapy; Simendan; Stroke Volume; Treatment Failure; Ventricular Dysfunction, Left	2017
Enhancement of myocardial function and reduction of injury with levosimendan after percutaneous coronary intervention for acute myocardial infarction: a pilot study. Cardiology, 2014, Volume: 128, Issue:2 Topics: Biomarkers; Cardiotonic Agents; Emergency Treatment; Female; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardial Stunning; Percutaneous Coronary Intervention; Pilot Projects; Pyridazines; Simendan; Treatment Outcome	2014
Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure. PloS one, 2014, Volume: 9, Issue:11 Topics: Aged; Biomarkers; C-Reactive Protein; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Intercellular Adhesion Molecule-1; Interleukin-6; Interleukin-8; Male; Matrix Metalloproteinase 9; Middle Aged; Morpholines; Myocardial Contraction; Myocardial Infarction; Pyridazines; Receptors, Interleukin-6; Recovery of Function; Simendan; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Ventricular Function, Left	2014
Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical care medicine, 2008, Volume: 36, Issue:8 Topics: Aged; Cardiotonic Agents; Coronary Care Units; Enoximone; Female; Hemodynamics; Hospital Mortality; Humans; Hydrazones; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Phosphodiesterase Inhibitors; Pyridazines; Shock, Cardiogenic; Simendan	2008
Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. European journal of heart failure, 2013, Volume: 15, Issue:5 Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Echocardiography; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Norway; Percutaneous Coronary Intervention; Pyridazines; Simendan; Treatment Outcome	2013
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). European heart journal, 2002, Volume: 23, Issue:18 Topics: Acute Disease; Aged; Analysis of Variance; Cardiotonic Agents; Double-Blind Method; Drug Evaluation; Endpoint Determination; Female; Heart Failure; Humans; Hydrazones; Hypotension; Male; Myocardial Infarction; Prospective Studies; Pyridazines; Risk Factors; Safety; Simendan; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left	2002
Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. American heart journal, 2005, Volume: 150, Issue:3 Topics: Angioplasty, Balloon, Coronary; Blood Flow Velocity; Coronary Circulation; Female; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Myocardial Infarction; Pyridazines; Simendan; Ventricular Dysfunction, Left	2005
Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2006, Volume: 19, Issue:2 Topics: Angioplasty, Balloon; Cardiotonic Agents; Echocardiography, Doppler; Humans; Hydrazones; Middle Aged; Myocardial Infarction; Prognosis; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left	2006
Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. European journal of heart failure, 2006, Volume: 8, Issue:7 Topics: Aged; Angioplasty, Balloon, Coronary; Cardiac Output; Cardiotonic Agents; Dobutamine; Female; Humans; Hydrazones; Infusions, Intravenous; Middle Aged; Myocardial Infarction; Pyridazines; Shock, Cardiogenic; Simendan; Treatment Outcome	2006
Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. International journal of cardiology, 2008, Jul-04, Volume: 127, Issue:2 Topics: Aged; Angioplasty, Balloon, Coronary; Cardiotonic Agents; Dobutamine; Female; Humans; Hydrazones; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyridazines; Shock, Cardiogenic; Simendan; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Left	2008
Strain rate analysis and levosimendan improve detection of myocardial viability by dobutamine echocardiography in patients with post-infarction left ventricular dysfunction: a pilot study. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2008, Volume: 21, Issue:9 Topics: Aged; Dobutamine; Drug Synergism; Echocardiography; Elasticity Imaging Techniques; Female; Humans; Hydrazones; Image Enhancement; Male; Myocardial Infarction; Pyridazines; Reproducibility of Results; Sensitivity and Specificity; Simendan; Ventricular Dysfunction, Left	2008
Heart failure update. European journal of heart failure, 1999, Volume: 1, Issue:3 Topics: Blood Pressure; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardial Infarction; Pyridazines; Safety; Simendan; Survival Rate; Treatment Outcome	1999

Other Studies

44 other study(ies) available for simendan and Cardiovascular Stroke

Article	Year
Levosimendan Postconditioning Attenuates Cardiomyocyte Apoptosis after Myocardial Infarction. Journal of healthcare engineering, 2022, Volume: 2022 Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Humans; Myocardial Infarction; Myocytes, Cardiac; Proto-Oncogene Proteins c-bcl-2; Rats; RNA, Messenger; Simendan	2022
The evaluation of levosimendan in patients with acute myocardial infarction related ventricular septal rupture undergoing cardiac surgery: a prospective observational cohort study with propensity score analysis. BMC anesthesiology, 2022, 05-03, Volume: 22, Issue:1 Topics: Acute Disease; Cardiac Surgical Procedures; Cardiotonic Agents; Female; Humans; Hydrazones; Male; Myocardial Infarction; Postoperative Complications; Propensity Score; Prospective Studies; Pyridazines; Simendan; Ventricular Septal Rupture	2022
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach. Current molecular pharmacology, 2023, Volume: 16, Issue:6 Topics: Antioxidants; Calcium; Collagen; Heart Failure; Hemodynamics; Humans; Isoproterenol; Myocardial Infarction; Ramipril; Simendan; Valsartan	2023
Impact of Ca Cardiovascular drugs and therapy, 2019, Volume: 33, Issue:5 Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Ischemic Preconditioning, Myocardial; Isolated Heart Preparation; Large-Conductance Calcium-Activated Potassium Channels; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Rats, Wistar; Simendan; Small-Conductance Calcium-Activated Potassium Channels	2019
Combination of Cyclosporine A and Levosimendan Induces Cardioprotection under Acute Hyperglycemia. International journal of molecular sciences, 2021, Apr-26, Volume: 22, Issue:9 Topics: Animals; Cardiotonic Agents; Cyclosporine; Disease Models, Animal; Heart; Hyperglycemia; Male; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Membranes; Mitochondrial Permeability Transition Pore; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Wistar; Simendan	2021
Cardioprotective and Anti-Aggregatory Effects of Levosimendan on Isoproterenol-Induced Myocardial Injury in High-Fat-Fed Rats Involves Modulation of PI3K/Akt/mTOR Signaling Pathway and Inhibition of Apoptosis: Comparison to Cilostazol. Journal of cardiovascular pharmacology and therapeutics, 2018, Volume: 23, Issue:5 Topics: Animals; Apoptosis; Cilostazol; Diet, High-Fat; Disease Models, Animal; Heart Rate; Inflammation Mediators; Isoproterenol; Lipids; Myocardial Infarction; Myocytes, Cardiac; Phosphatidylinositol 3-Kinase; Platelet Aggregation; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Simendan; TOR Serine-Threonine Kinases	2018
Preconditioning by Levosimendan is Mediated by Activation of Mitochondrial Ca Cardiovascular drugs and therapy, 2018, Volume: 32, Issue:5 Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Indoles; Isolated Heart Preparation; Large-Conductance Calcium-Activated Potassium Channels; Male; Mitochondria, Heart; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Potassium Channel Blockers; Rats, Wistar; Simendan; Ventricular Function, Left	2018
Early 'in-lab' use of levosimendan in patients with cardiogenic shock unsuitable for intra-aortic balloon pump counterpulsation. Therapeutic advances in cardiovascular disease, 2014, Volume: 8, Issue:1 Topics: Aged; Cardiotonic Agents; Counterpulsation; Humans; Hydrazones; Infusions, Intravenous; Intra-Aortic Balloon Pumping; Myocardial Infarction; Percutaneous Coronary Intervention; Pyridazines; Shock, Cardiogenic; Simendan; Time Factors; Treatment Outcome	2014
Levosimendan improves contractility in vivo and in vitro in a rodent model of post-myocardial infarction heart failure. Acta physiologica (Oxford, England), 2014, Volume: 210, Issue:4 Topics: Animals; Calcium; Cardiotonic Agents; Female; Heart Failure; Hydrazones; Myocardial Infarction; Pyridazines; Rats; Rats, Sprague-Dawley; Simendan	2014
Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro. Thrombosis and haemostasis, 2015, Volume: 113, Issue:2 Topics: Anti-Inflammatory Agents; Cell Adhesion; Cells, Cultured; Decanoic Acids; E-Selectin; Enzyme-Linked Immunosorbent Assay; Heart Failure; Human Umbilical Vein Endothelial Cells; Humans; Hydrazones; Hydroxy Acids; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-6; Interleukin-8; Microcirculation; Microscopy, Fluorescence; Muscle Cells; Myocardial Infarction; Myocytes, Cardiac; Necrosis; Neutrophils; NF-kappa B; Phosphorylation; Pyridazines; Reactive Oxygen Species; Simendan; Vasodilator Agents	2015
Effect of levosimendan therapy on myocardial infarct size and left ventricular function after acute coronary occlusion. Heart (British Cardiac Society), 2016, Volume: 102, Issue:6 Topics: Acute Disease; Animals; Cardiotonic Agents; Coronary Occlusion; Diastole; Disease Models, Animal; Follow-Up Studies; Hydrazones; Male; Myocardial Contraction; Myocardial Infarction; Myocardium; Pyridazines; Simendan; Stroke Volume; Swine; Systole; Ventricular Function, Left; Ventricular Remodeling	2016
Levosimendan Pretreatment Inhibits Myocardial Apoptosis in Swine after Coronary Microembolization. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 41, Issue:1 Topics: Animals; Apoptosis; Caspase 3; Down-Regulation; Echocardiography; Heart Ventricles; Hydrazones; Microspheres; Myocardial Infarction; Myocardium; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridazines; RNA Interference; RNA, Small Interfering; Signal Transduction; Simendan; Swine; Troponin I; Vasodilator Agents	2017
Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction. Acute cardiac care, 2008, Volume: 10, Issue:3 Topics: Aged; Cardiac Output; Cardiotonic Agents; Combined Modality Therapy; Female; Hemodynamics; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Male; Middle Aged; Myocardial Infarction; Norepinephrine; Prospective Studies; Pyridazines; Shock, Cardiogenic; Simendan; Vasoconstrictor Agents; Ventricular Dysfunction, Left	2008
Levosimendan in heart failure after surgical repair of cardiac rupture. Minerva cardioangiologica, 2009, Volume: 57, Issue:1 Topics: Aged; Cardiotonic Agents; Female; Heart Failure; Heart Rupture; Humans; Hydrazones; Myocardial Infarction; Pyridazines; Simendan; Treatment Outcome	2009
Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance. Acute cardiac care, 2009, Volume: 11, Issue:2 Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Phosphodiesterase Inhibitors; Pyridazines; Retrospective Studies; Shock, Cardiogenic; Simendan; Time Factors; Treatment Outcome; Vascular Resistance	2009
Anti-ischemic effects of inotropic agents in experimental right ventricular infarction. Acta anaesthesiologica Scandinavica, 2009, Volume: 53, Issue:7 Topics: Animals; Blood Gas Analysis; Cardiotonic Agents; Dobutamine; Female; Heart Ventricles; Hemodynamics; Hydrazones; Inflammation Mediators; Milrinone; Myocardial Infarction; Myocardial Ischemia; Myocarditis; Myocardium; Myoglobin; Neutrophil Infiltration; Pyridazines; Simendan; Swine; Troponin T	2009
Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Critical care medicine, 2009, Volume: 37, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Hemodynamics; Humans; Hydrazones; Middle Aged; Myocardial Infarction; Pyridazines; Shock, Cardiogenic; Simendan; Vasodilator Agents; Ventricular Function, Left; Ventricular Function, Right	2009
Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Critical care medicine, 2009, Volume: 37, Issue:9 Topics: Cardiotonic Agents; Enoximone; Humans; Hydrazones; Myocardial Infarction; Pyridazines; Shock, Cardiogenic; Simendan	2009
Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats. Journal of hypertension, 2009, Volume: 27, Issue:10 Topics: Administration, Oral; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cardiotonic Agents; Cyclin-Dependent Kinase Inhibitor p16; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Heart Failure; Homeodomain Proteins; Hydrazones; Male; Myocardial Infarction; Pyridazines; Rats; Rats, Mutant Strains; Rats, Wistar; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; STAT1 Transcription Factor; Ventricular Remodeling	2009
Do it right? Critical care medicine, 2009, Volume: 37, Issue:12 Topics: Humans; Hydrazones; Myocardial Infarction; Pyridazines; Shock, Cardiogenic; Simendan; Vasodilator Agents; Ventricular Function, Right	2009
Superiority of levosimendan over dobutamine in right ventricle failure. Critical care medicine, 2010, Volume: 38, Issue:1 Topics: Cardiotonic Agents; Critical Care; Critical Illness; Dobutamine; Female; Heart Function Tests; Humans; Hydrazones; Hypertension, Pulmonary; Intensive Care Units; Male; Myocardial Infarction; Prognosis; Pyridazines; Shock, Cardiogenic; Simendan; Survival Rate; Treatment Outcome; Vascular Resistance; Ventricular Dysfunction, Right	2010
Concomitant levosimendan and esmolol infusion in ischaemic cardiogenic shock. British journal of anaesthesia, 2010, Volume: 104, Issue:3 Topics: Adrenergic beta-Antagonists; Cardiotonic Agents; Drug Therapy, Combination; Humans; Hydrazones; Male; Middle Aged; Myocardial Infarction; Propanolamines; Pyridazines; Shock, Cardiogenic; Simendan	2010
Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction. Vascular health and risk management, 2010, Sep-07, Volume: 6 Topics: Age Factors; Aged; Atrial Fibrillation; Cardiotonic Agents; Chi-Square Distribution; Cohort Studies; Electrocardiography; Female; Heart Arrest; Humans; Hydrazones; Length of Stay; Male; Myocardial Infarction; Myocardial Revascularization; Proportional Hazards Models; Pyridazines; Sex Factors; Shock, Cardiogenic; Simendan; Statistics, Nonparametric	2010
Management of acute cardiac failure by intracoronary administration of levosimendan. Journal of cardiovascular pharmacology, 2011, Volume: 58, Issue:3 Topics: Acute Disease; Aged; Aged, 80 and over; Blood Pressure; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Female; Heart; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydrazones; Injections, Intra-Arterial; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pyridazines; Simendan; Vascular Resistance; Ventricular Function, Left	2011
Effects of levosimendan on cardiac gene expression profile and post-infarct cardiac remodelling in diabetic Goto-Kakizaki rats. Basic & clinical pharmacology & toxicology, 2011, Volume: 109, Issue:5 Topics: Animals; Diabetes Mellitus, Experimental; Down-Regulation; Gene Expression Profiling; Heart; Heart Failure; Hydrazones; Immunohistochemistry; Microarray Analysis; Myocardial Infarction; Myocardium; Pyridazines; Rats; Rats, Wistar; Renin-Angiotensin System; Simendan; Transcriptome; Up-Regulation; Ventricular Remodeling	2011
Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts. Cardiovascular diabetology, 2012, Jan-12, Volume: 11 Topics: Animals; Blood Glucose; Disease Models, Animal; Hemodynamics; Hydrazones; Hyperglycemia; Male; Milrinone; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Pyridazines; Rats; Rats, Wistar; Simendan; Time Factors	2012
Positive inotropy for acute heart failure complicating myocardial infarction. European heart journal, 2002, Volume: 23, Issue:18 Topics: Acute Disease; Cardiotonic Agents; Clinical Trials as Topic; Drug Evaluation; Heart Failure; Humans; Hydrazones; Myocardial Infarction; Pyridazines; Simendan; Treatment Outcome; Ventricular Dysfunction, Left	2002
[Is levosimendan an inoprotective drug in patients with acute coronary syndrome undergoing surgical revascularization?]. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2003, Volume: 38, Issue:9 Topics: Adult; Aged; ATP-Binding Cassette Transporters; Cardiotonic Agents; Coronary Disease; Female; Hemodynamics; Humans; Hydrazones; KATP Channels; Male; Middle Aged; Mitral Valve Insufficiency; Myocardial Infarction; Myocardial Revascularization; Potassium Channels; Potassium Channels, Inwardly Rectifying; Pyridazines; Simendan	2003
[Levosimendan-long-term inodilation in an infant with myocardial infarction]. Zeitschrift fur Kardiologie, 2004, Volume: 93, Issue:3 Topics: Cardiac Output, Low; Cardiotonic Agents; Coronary Stenosis; Coronary Vessel Anomalies; Echocardiography, Doppler; Electrocardiography, Ambulatory; Humans; Hydrazones; Hypertension, Pulmonary; Infant; Infant, Newborn; Long-Term Care; Male; Myocardial Infarction; Postoperative Complications; Pulmonary Artery; Pulmonary Wedge Pressure; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Vascular Resistance; Vasodilator Agents	2004
Levosimendan in septic cardiac failure. Intensive care medicine, 2005, Volume: 31, Issue:1 Topics: Adult; Aged; Cardiotonic Agents; Female; Hemodynamics; Humans; Hydrazones; Male; Myocardial Infarction; Pyridazines; Shock, Septic; Simendan	2005
[Treatment of cardiogenic shock with the Ca2+ sensitizer levosimendan]. Medizinische Klinik (Munich, Germany : 1983), 2004, Dec-15, Volume: 99, Issue:12 Topics: Adult; Angioplasty, Balloon, Coronary; Cardiotonic Agents; Catheterization, Swan-Ganz; Coronary Stenosis; Drug Therapy, Combination; Hemodynamics; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Male; Myocardial Infarction; Pyridazines; Receptors, Calcium-Sensing; Shock, Cardiogenic; Simendan; Stents; Vasodilator Agents	2004
Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases. Journal of clinical pharmacology, 2005, Volume: 45, Issue:6 Topics: Aged; Angioplasty, Balloon, Coronary; Atrial Fibrillation; Calcium Channel Blockers; Cardiotonic Agents; Electrocardiography; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Middle Aged; Myocardial Infarction; Myocardial Stunning; Pericarditis; Pyridazines; Respiration, Artificial; Shock, Cardiogenic; Simendan; Ventricular Dysfunction, Left	2005
[Cardiogenic shock-- new therapeutic strategies]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2005, May-19, Volume: 125, Issue:10 Topics: Cardiotonic Agents; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pyridazines; Shock, Cardiogenic; Simendan	2005
Treatment of cardiogenic shock with levosimendan in combination with beta-adrenergic antagonists. British journal of anaesthesia, 2005, Volume: 95, Issue:5 Topics: Adrenergic beta-Antagonists; Cardiotonic Agents; Drug Therapy, Combination; Humans; Hydrazones; Male; Middle Aged; Myocardial Infarction; Propanolamines; Pyridazines; Shock, Cardiogenic; Simendan	2005
[Successful use of levosimendan in a patient with cardiogenic shock complicating acute myocardial infarction]. La Tunisie medicale, 2005, Volume: 83, Issue:10 Topics: Cardiotonic Agents; Humans; Hydrazones; Male; Middle Aged; Myocardial Infarction; Pyridazines; Shock, Cardiogenic; Simendan; Stroke Volume; Treatment Outcome	2005
Levosimendan improves cardiopulmonary resuscitation and survival by K(ATP) channel activation. Journal of the American College of Cardiology, 2006, Mar-07, Volume: 47, Issue:5 Topics: Adenosine Triphosphate; Animals; Cardiopulmonary Resuscitation; Cardiotonic Agents; Hydrazones; Male; Myocardial Infarction; Potassium Channels; Pyridazines; Rats; Rats, Sprague-Dawley; Simendan; Survival Rate	2006
The 2005 Scientific Sessions of the American Heart Association (AHA). Heart failure monitor, 2006, Volume: 5, Issue:1 Topics: American Heart Association; Animals; Cardiotonic Agents; Heart Failure; Hematopoietic Stem Cell Transplantation; Home Care Services; Humans; Hydrazones; Monitoring, Physiologic; Myocardial Infarction; Pacemaker, Artificial; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome; United States	2006
Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model. Journal of cardiovascular pharmacology, 2006, Volume: 48, Issue:4 Topics: Animals; Diastole; Hydrazones; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Pyridazines; Rabbits; Simendan; Ventricular Function, Left	2006
Effects of levosimendan on myocardial infarct size and hemodynamics in a closed-chest porcine ischemia-reperfusion model. Cardiovascular drugs and therapy, 2006, Volume: 20, Issue:5 Topics: Animals; Blood Pressure; Cardiac Output; Cardiotonic Agents; Female; Heart Ventricles; Hydrazones; Myocardial Infarction; Myocardial Reperfusion; Pyridazines; Simendan; Swine; Vasodilator Agents; Ventricular Function	2006
Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model. Vascular pharmacology, 2007, Volume: 47, Issue:4 Topics: Adenosine Triphosphate; Anesthesia; Animals; Arrhythmias, Cardiac; Blood Pressure; Heart Rate; Hydrazones; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Nitric Oxide; Nitric Oxide Synthase Type II; Potassium Channels; Pyridazines; Rabbits; Simendan	2007
Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute cardiac care, 2008, Volume: 10, Issue:1 Topics: Aged; Angioplasty, Balloon, Coronary; Cardiotonic Agents; Female; Hemodynamics; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Male; Myocardial Contraction; Myocardial Infarction; Pulmonary Artery; Pyridazines; Shock, Cardiogenic; Simendan; Time Factors; Vascular Resistance	2008
A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. British journal of pharmacology, 2008, Volume: 154, Issue:1 Topics: Animals; Blotting, Western; Cardiac Output; Cardiotonic Agents; Coronary Circulation; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Guinea Pigs; Hydrazones; In Vitro Techniques; Ischemic Preconditioning, Myocardial; KATP Channels; Myocardial Infarction; Myocardium; Pyridazines; Signal Transduction; Simendan	2008
Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesthesia and analgesia, 2000, Volume: 90, Issue:1 Topics: Animals; ATP-Binding Cassette Transporters; Cardiotonic Agents; Dogs; Glyburide; Hemodynamics; Hydrazones; Hypoglycemic Agents; KATP Channels; Microspheres; Myocardial Infarction; Potassium Channels; Potassium Channels, Inwardly Rectifying; Pyridazines; Simendan; Ventricular Function, Left	2000
Improved survival with simendan after experimental myocardial infarction in rats. European journal of pharmacology, 2001, May-11, Volume: 419, Issue:2-3 Topics: Animals; Antihypertensive Agents; Cardiotonic Agents; Enalapril; Hydrazones; Male; Milrinone; Myocardial Infarction; Pyridazines; Rats; Rats, Wistar; Simendan	2001